Accès gratuit
Numéro
Therapie
Volume 65, Numéro 4, Juillet-Août 2010
Page(s) 285 - 290
Section Physiopathologie / Physiopathology
DOI https://doi.org/10.2515/therapie/2010040
Publié en ligne 21 septembre 2010
  1. CHMP 2008. Guideline on medicinal products for the treatment of Alzheimer’s disease and other dementias. http://www.emea.europa.eu/pdfs/human/ewp/\T1\O55395en.pdf
  2. Lathia CD, Amakye D, Dai W, et al. State of the art. The value, qualification, and regulatory use of surrogate end points in drug development. Clinical Pharmacology & Therapeutics 2009; 86 (1): 32-43 [CrossRef]
  3. Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009; 66(5): 638-45 [CrossRef] [PubMed]
  4. Jack CR, Bernstein MA, Borowski BJ, et al. Update on the magnetic resonance imaging core of the Alzheimer’s disease neuroimaging initiative. Alzheimer’s & Dementia 2010; 6(3): 212-20 [CrossRef]
  5. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer’s disease neuroimaging initiative positron emission tomography core. Alzheimer’s & Dementia 2010; 6(3): 221-9 [CrossRef]
  6. Walhovd KB, Fjell AM, Brewer J, et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. American Journal of Neuroradiology 2010; 31: 347-54 [CrossRef]
  7. Van der Vlies AE, Verwey NA, Bouwman FH, et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer Disease SYMBOL. Neurology 2009; 72(12): 1056-61 [CrossRef] [PubMed]
  8. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of AD. EMBO Molecular Medicine 2009; 1(8-9): 371-80 [CrossRef] [PubMed]
  9. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet 2007; 6: 734-46 [CrossRef] [PubMed]
  10. Vellas B, Andrieu S, Aisen P, et al. for the Oxford Task Force Group. Biomarkers for Alzheimer’s disease therapeutic trials: The Oxford Task Force. Forthcoming

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.